• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

早期管腔型乳腺癌中 MMP-11 的表达：与临床、MRI、病理特征及无病生存的相关性。

MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.

机构信息

Institute of Genetics and Molecular and Cellular Biology, Illkirch, France.

Centre National de la Recherche Scientifique, UMR 7104, Illkirch, France.

出版信息

BMC Cancer. 2024 Mar 4;24(1):295. doi: 10.1186/s12885-024-11998-0.

DOI:10.1186/s12885-024-11998-0
PMID:38438841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10913243/
Abstract

BACKGROUND

Early hormone-positive breast cancers typically have favorable outcomes, yet long-term surveillance is crucial due to the risk of late recurrences. While many studies associate MMP-11 expression with poor prognosis in breast cancer, few focus on early-stage cases. This study explores MMP-11 as an early prognostic marker in hormone-positive breast cancers.

METHODS

In this retrospective study, 228 women with early hormone-positive invasive ductal carcinoma, treated surgically between 2011 and 2016, were included. MMP-11 expression was measured by immunohistochemistry, and its association with clinical and MRI data was analyzed.

RESULTS

Among the patients (aged 31-89, median 60, with average tumor size of 15.7 mm), MMP-11 staining was observed in half of the cases. This positivity correlated with higher uPA levels and tumor grade but not with nodal status or size. Furthermore, MMP-11 positivity showed specific associations with MRI features. Over a follow-up period of 6.5 years, only 12 oncological events occurred. Disease-free survival was linked to Ki67 and MMP-11.

CONCLUSION

MMP-11, primarily present in tumor-surrounding stromal cells, correlates with tumor grade and uPA levels. MMP-11 immunohistochemical score demonstrates a suggestive trend in association with disease-free survival, independent of Ki67 and other traditional prognostic factors. This highlights the potential of MMP-11 as a valuable marker in managing early hormone-positive breast cancer.

摘要

背景

早期激素阳性乳腺癌通常具有良好的预后，但由于存在晚期复发的风险，长期监测至关重要。尽管许多研究表明 MMP-11 表达与乳腺癌的不良预后相关，但很少有研究关注早期病例。本研究探讨了 MMP-11 作为激素阳性乳腺癌的早期预后标志物。

方法

在这项回顾性研究中，纳入了 2011 年至 2016 年间接受手术治疗的 228 例早期激素阳性浸润性导管癌女性患者。通过免疫组织化学检测 MMP-11 的表达，并分析其与临床和 MRI 数据的关联。

结果

在这些患者（年龄 31-89 岁，中位年龄 60 岁，平均肿瘤大小为 15.7mm）中，有一半病例观察到 MMP-11 染色阳性。这种阳性与较高的 uPA 水平和肿瘤分级相关，但与淋巴结状态或大小无关。此外，MMP-11 阳性与 MRI 特征具有特异性关联。在 6.5 年的随访期间，仅发生了 12 例肿瘤事件。无病生存与 Ki67 和 MMP-11 相关。

结论

MMP-11 主要存在于肿瘤周围的基质细胞中，与肿瘤分级和 uPA 水平相关。MMP-11 免疫组化评分与无病生存呈显著相关趋势，独立于 Ki67 和其他传统预后因素。这突显了 MMP-11 作为管理早期激素阳性乳腺癌的有价值标志物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/d8457618c674/12885_2024_11998_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/b53cb1af71f7/12885_2024_11998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/2e4864cfab55/12885_2024_11998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/ecb35c1d41dc/12885_2024_11998_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/dc47645d11b0/12885_2024_11998_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/3612d60eba55/12885_2024_11998_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/7e9380e78eb5/12885_2024_11998_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/d8457618c674/12885_2024_11998_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/b53cb1af71f7/12885_2024_11998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/2e4864cfab55/12885_2024_11998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/ecb35c1d41dc/12885_2024_11998_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/dc47645d11b0/12885_2024_11998_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/3612d60eba55/12885_2024_11998_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/7e9380e78eb5/12885_2024_11998_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02bd/10913243/d8457618c674/12885_2024_11998_Fig7_HTML.jpg

相似文献

1
MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.早期管腔型乳腺癌中 MMP-11 的表达：与临床、MRI、病理特征及无病生存的相关性。
BMC Cancer. 2024 Mar 4;24(1):295. doi: 10.1186/s12885-024-11998-0.
2
MMP-1 expression has an independent prognostic value in breast cancer.MMP-1 的表达在乳腺癌中有独立的预后价值。
BMC Cancer. 2011 Aug 11;11:348. doi: 10.1186/1471-2407-11-348.
3
Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblast-like cells adjacent to invasive ductal carcinoma of the breast.MMP-11 表达在乳腺浸润性导管癌周围基质成纤维细胞样细胞中的诊断和预后相关性。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S433-42. doi: 10.1245/s10434-012-2734-3. Epub 2012 Nov 1.
4
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.肿瘤源性基质金属蛋白酶-13（MMP-13）与浸润性乳腺癌的不良预后相关。
BMC Cancer. 2008 Mar 28;8:83. doi: 10.1186/1471-2407-8-83.
5
Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.基质金属蛋白酶-2（MMP-2）、基质金属蛋白酶-9（MMP-9）和氨基肽酶 N/CD13 在乳腺癌患者中的预后价值。
Med Oncol. 2012 Jun;29(2):561-9. doi: 10.1007/s12032-011-9984-y. Epub 2011 May 25.
6
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.基质金属蛋白酶（MMP）-2和MMP-9在乳腺癌中的表达：特别提及激活蛋白-2、人表皮生长因子受体2（HER2）及预后
Clin Cancer Res. 2004 Nov 15;10(22):7621-8. doi: 10.1158/1078-0432.CCR-04-1061.
7
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.新辅助化疗前后Ki67表达在HR阴性乳腺癌中的预后价值
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.
8
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
9
Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.沙特人群早期乳腺癌肿瘤中Oncotype Dx评分与肿瘤分级、大小、淋巴结状态、增殖标志物Ki67及诺丁汉预后指数的关系。
Ann Diagn Pathol. 2021 Apr;51:151674. doi: 10.1016/j.anndiagpath.2020.151674. Epub 2020 Nov 25.
10
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.早期浸润性乳腺癌中尿激酶激活纤溶酶原（uPA）及其抑制剂（PAI-1）血清水平与激素及HER-2状态的相关性
Med Arch. 2018 Nov;72(5):335-340. doi: 10.5455/medarh.2018.72.335-340.

引用本文的文献

1
An Integrative Multi-Omics Random Forest Framework for Robust Biomarker Discovery.一种用于稳健生物标志物发现的综合多组学随机森林框架。
bioRxiv. 2025 Mar 6:2025.03.05.641533. doi: 10.1101/2025.03.05.641533.
2
Correlation Between Ki-67 Expression and Tumor Grade in Breast Cancer: A Cross-Sectional Study.乳腺癌中Ki-67表达与肿瘤分级的相关性：一项横断面研究。
Cureus. 2024 Dec 23;16(12):e76239. doi: 10.7759/cureus.76239. eCollection 2024 Dec.
3
Cancer-associated fibroblast-derived MMP11 promotes tumor progression in pancreatic cancer.

本文引用的文献

1
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.人表皮生长因子受体 2 检测在乳腺癌中的应用。
Arch Pathol Lab Med. 2023 Sep 1;147(9):993-1000. doi: 10.5858/arpa.2023-0950-SA.
2
A Focus on the Synergy of Radiomics and RNA Sequencing in Breast Cancer.聚焦于放射组学和 RNA 测序在乳腺癌中的协同作用。
Int J Mol Sci. 2023 Apr 13;24(8):7214. doi: 10.3390/ijms24087214.
3
Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.肿瘤微环境中癌症相关成纤维细胞和免疫细胞的代谢重编程及串扰。
癌症相关成纤维细胞衍生的基质金属蛋白酶11促进胰腺癌的肿瘤进展。
Cancer Sci. 2025 Mar;116(3):643-655. doi: 10.1111/cas.16418. Epub 2024 Dec 5.
4
Introducing effective genes in lymph node metastasis of breast cancer patients using SHAP values based on the mRNA expression data.利用基于 mRNA 表达数据的 SHAP 值，为乳腺癌淋巴结转移患者引入有效基因。
PLoS One. 2024 Aug 16;19(8):e0308531. doi: 10.1371/journal.pone.0308531. eCollection 2024.
Front Endocrinol (Lausanne). 2022 Aug 15;13:988295. doi: 10.3389/fendo.2022.988295. eCollection 2022.
4
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis.乳腺癌患者首次诊断后 10-32 年内的复发情况。
J Natl Cancer Inst. 2022 Mar 8;114(3):391-399. doi: 10.1093/jnci/djab202.
5
De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?早期激素受体阳性乳腺癌内分泌治疗的降级：何时局部治疗足够？
Ann Surg. 2021 Oct 1;274(4):654-663. doi: 10.1097/SLA.0000000000005064.
6
A single-cell and spatially resolved atlas of human breast cancers.人类乳腺癌的单细胞和空间分辨图谱。
Nat Genet. 2021 Sep;53(9):1334-1347. doi: 10.1038/s41588-021-00911-1. Epub 2021 Sep 6.
7
Peritumoral edema in breast cancer at preoperative MRI: an interpretative study with histopathological review toward understanding tumor microenvironment.术前 MRI 乳腺癌瘤周水肿：一项具有组织病理学复查的解读性研究，旨在了解肿瘤微环境。
Sci Rep. 2021 Jun 21;11(1):12992. doi: 10.1038/s41598-021-92283-z.
8
Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression.多组学标志物分析可实现乳腺癌进展的早期预测。
Front Genet. 2021 Jun 3;12:670749. doi: 10.3389/fgene.2021.670749. eCollection 2021.
9
Matrix Metalloproteinase-11 Promotes Early Mouse Mammary Gland Tumor Growth through Metabolic Reprogramming and Increased IGF1/AKT/FoxO1 Signaling Pathway, Enhanced ER Stress and Alteration in Mitochondrial UPR.基质金属蛋白酶-11通过代谢重编程和增加IGF1/AKT/FoxO1信号通路、增强内质网应激以及改变线粒体未折叠蛋白反应来促进小鼠早期乳腺肿瘤生长。
Cancers (Basel). 2020 Aug 20;12(9):2357. doi: 10.3390/cancers12092357.
10
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.高危 ER 阳性乳腺癌患者远处复发的高估：CTS5 风险评分在 TEAM 和 IDEAL 试验中的有效性和准确性。
J Clin Oncol. 2020 Oct 1;38(28):3273-3281. doi: 10.1200/JCO.19.02427. Epub 2020 Jul 24.